Trial Profile
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Retifanlimab (Primary) ; SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BriaCell Therapeutics Corp
- 07 Feb 2024 According to a BriaCell Therapeutics Corp Media Release, company looks forward to presenting further updates as treatment progresses in the fully enrolled Phase 2 study.
- 07 Feb 2024 Preliminary disease control rate results presented in a BriaCell Therapeutics Corp Media Release.
- 04 Jan 2024 According to a BriaCell Therapeutics Corp media release, company released transformational images of remarkable responder from phase portion of this Phase 2 study of Bria-IMT combination regimen. Company looking forward to sharing additional data in the coming months.